A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

Objectives. Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Full description

Saved in:
Bibliographic Details
Main Authors: Dawn Odom, Deirdre Mladsi, Molly Purser, James A. Kaye, Eirini Palaka, Alina Charter, Jo Annah Jensen, Dalila Sellami
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Journal of Skin Cancer
Online Access:http://dx.doi.org/10.1155/2017/6121760
Tags: Add Tag
No Tags, Be the first to tag this record!